The role of physical activity against chemotherapy-induced peripheral neuropathy: a narrative review

Daniele Diotti , Luca Puce , Laura Mori , Carlo Trompetto , Elena Saretti , Cecilia Contenti , Lucio Marinelli

Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (2) : 87 -99.

PDF (1410KB)
Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (2) :87 -99. DOI: 10.37349/ent.2022.00020
Review
research-article
The role of physical activity against chemotherapy-induced peripheral neuropathy: a narrative review
Author information +
History +
PDF (1410KB)

Abstract

Several studies investigated the side effect of adjuvant cancer treatments, and different types of preventive techniques or treatments have been assessed. Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurological side effect. Exercise training has been widely studied as an adjuvant therapy to prevent CIPN and improve post-chemotherapy functional outcome and quality of life (QoL). This narrative review aims to summarize the data obtained from the latest studies about physical activity (PA) for the prevention and treatment of CIPN and associated QoL measures. Literature research was conducted to obtain studies including PA interventions for patients with CIPN. Ten studies met inclusion criteria and were therefore summarized and discussed, focusing on exercise type and functional outcome. It seems clear that, regardless of the type of exercise, PA plays a positive role in the treatment of CIPN, providing a significant symptom improvement. There has been no standardization of type, quantity, and intensity of PA administered to the subjects in the various studies probably due to a physiological difference between samples, grade of neuropathy, and difference among therapies.

Keywords

Chemotherapy-induced peripheral neuropathy / cancer / physical activity / treatment / prevention

Cite this article

Download citation ▾
Daniele Diotti, Luca Puce, Laura Mori, Carlo Trompetto, Elena Saretti, Cecilia Contenti, Lucio Marinelli. The role of physical activity against chemotherapy-induced peripheral neuropathy: a narrative review. Exploration of Neuroprotective Therapy, 2022, 2 (2) : 87-99 DOI:10.37349/ent.2022.00020

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69: 363-85.

[2]

Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl N, et al. Pain in cancer survivors. J Clin Oncol. 2014; 32: 1739-47.

[3]

Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014; 155: 2461-70.

[4]

Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017; 17: 47.

[5]

Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019; 20: 1451.

[6]

Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007; 39: 1423-34.

[7]

Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, et al.; 2006 Nutrition, Physical Activity and Cancer Survivorship Advisory Committee; American Cancer Society. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2006; 56: 323-53.

[8]

Physical Activities Guidelines Advisory Committee. Physical activity guidelines advisory committee report, 2008 [Internet]. Washington (DC): U.S. Department of Health and Human Services; [cited 2022 Jan 26]. Available from: https://health.gov/sites/default/files/2019-10/CommitteeReport_7.pdf

[9]

Stefani L, Galanti G, Klika R. Clinical implementation of exercise guidelines for cancer patients: adaptation of ACSM’s guidelines to the Italian model. J Funct Morphol Kinesiol. 2017; 2: 4.

[10]

Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016; 73: 860-6.

[11]

Kneis S, Wehrle A, Müller J, Maurer C, Ihorst G, Gollhofer A, et al. It’s never too late-balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. BMC Cancer. 2019; 19: 414.

[12]

Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol. 2014; 25: 493-9.

[13]

Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018; 26: 1019-28.

[14]

Vollmers PL, Mundhenke C, Maass N, Bauerschlag D, Kratzenstein S, Röcken C, et al. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. J Cancer Res Clin Oncol. 2018; 144: 1785-92.

[15]

Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2018; 26: 615-24.

[16]

Henke CC, Cabri J, Fricke L, Pankow W, Kandilakis G, Feyer PC, et al. Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer. 2014; 22: 95-101.

[17]

Wonders KY, Whisler G, Loy H, Holt B, Bohachek K, Wise R. Ten weeks of home-based exercise attenuates symptoms of chemotherapy-induced peripheral neuropathy in breast cancer patients. Health Psychol Res. 2013; 1: e28.

[18]

Andersen Hammond E, Pitz M, Steinfeld K, Lambert P, Shay B. An exploratory randomized trial of physical therapy for the treatment of chemotherapy-induced peripheral neuropathy. Neurorehabil Neural Repair. 2020; 34: 235-46.

[19]

van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol. 2015; 33: 1918-27.

[20]

McCrary JM, Goldstein D, Sandler CX, Barry BK, Marthick M, Timmins HC, et al. Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2019; 27: 3849-57.

[21]

Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20: 1767-74.

[22]

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012; 82: 51-77.

[23]

Bonhof CS, van de Poll-Franse LV, Wasowicz DK, Beerepoot LV, Vreugdenhil G, Mols F. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J Cancer Surviv. 2021; 15: 190-200.

[24]

Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017; 10: 174.

[25]

Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol. 2020; 145: 102831.

[26]

Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav. 2016; 7: e00558.

[27]

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013; 119: 438-44.

[28]

Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017; 8: 86.

[29]

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al.; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2014; 32: 1941-67.

[30]

Jordan B, Jahn F, Sauer S, Jordan K. Prevention and management of chemotherapy-induced polyneuropathy. Breast Care (Basel). 2019; 14: 79-84.

[31]

Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol. 2016; 140: 176-83.

[32]

Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019; 17: 184-96.

[33]

Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. J Natl Cancer Inst. 2018; 110: 141-8.

[34]

Bailey AG, Brown JN, Hammond JM. Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: a systematic review. J Oncol Pharm Pract. 2021; 27: 156-64.

[35]

Shigematsu H, Kimura Y, Itagaki T, Yasui D. Preventive effect of cryotherapy on persistent chemotherapy-induced peripheral neuropathy after completion of weekly paclitaxel therapy for breast cancer. Version: 1. [Preprint]. [cited 2022 Jan 26]. Available from: https://europepmc.org/article/PPR/PPR338488#impact

[36]

Tsuyuki S, Senda N, Kanng Y, Yamaguchi A, Yoshibayashi H, Kikawa Y, et al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat. 2016;160:61-7.

[37]

Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Kataoka A, et al. Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial. BMC Cancer. 2021; 21: 548.

[38]

Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, et al. Pilot evaluation of scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2015; 23: 943-51.

[39]

Loprinzi C, Le-Rademacher JG, Majithia N, McMurray RP, O’Neill CR, Bendel MA, et al. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020; 28: 1183-97.

[40]

Li Y, Lustberg MB, Hu S. Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy. Cancers (Basel). 2021; 13: 766.

[41]

Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2016; 9: CD005001.

[42]

Park JS, Kim S, Hoke A. An exercise regimen prevents development paclitaxel induced peripheral neuropathy in a mouse model. J Peripher Nerv Syst. 2015; 20: 7-14.

[43]

Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012; 20: 583-9.

[44]

Kanzawa-Lee GA, Larson JL, Resnicow K, Smith EML. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 2020; 43: E172-85.

[45]

Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, et al. Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy. Br J Cancer. 2014; 111: 1718-25.

[46]

Park SB, Alberti P, Kolb NA, Gewandter JS, Schenone A, Argyriou AA. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019; 24: S13-25.

[47]

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, et al.; CI-PeriNomS Group. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014; 25: 257-64.

[48]

Brown JK, Byers T, Doyle C, Coumeya KS, Demark-Wahnefried W, Kushi LH, et al.; American Cancer Society. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2003; 53: 268-91.

[49]

Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv. 2015; 9: 512-22.

[50]

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-76.

[51]

Müller J, Weiler M, Schneeweiss A, Haag GM, Steindorf K, Wick W, et al. Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial. Br J Cancer. 2021; 125: 955-65.

[52]

van Vulpen JK, Peeters PH, Velthuis MJ, van der Wall E, May AM. Effects of physical exercise during adjuvant breast cancer treatment on physical and psychosocial dimensions of cancer-related fatigue: a meta-analysis. Maturitas. 2016; 85: 104-11.

PDF (1410KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉